Recruiting
Phase 2

XL092 & Pembrolizumab

Sponsor:

UNC Lineberger Comprehensive Cancer Center

Code:

NCT07484139

Conditions

Oral Cavity Squamous Cell Carcinoma

Head and Neck Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

XL092

Pembrolizumab

Study Details

Brief summary:

This is a multicenter, single arm Phase 2B study in subjects with locally advanced oral cavity squamous cell carcinoma (OCSCC) with surgically resectable disease. The study will assess the combination of neoadjuvant XL092 and pembrolizumab for safety and improvement of pathologic response rates compared to historical standard of care with perioperative pembrolizumab. The primary objective is to estimate the pathologic response rate defined as either pathological complete response (pCR), which is the absence of residual viable tumor, or major pathologic response (MPR), which is <10% of residual tumor following the completion of neoadjuvant therapy and surgery. The study will be conducted in two stages. Per Simon's Stage 1, 11 patients will be enrolled. Simon Stage 2 will be gated on multiple factors. If ≥2 pathologic response is observed (pCR or MPR), the trial will proceed with cohort expansion and enroll an additional 15 patients for a total of 26 patients.

Conditions

Oral Cavity Squamous Cell Carcinoma

Head and Neck Cancer

Study ID

NCT07484139

Start date

Sep 22, 2026

Status verified date

Nov, 2026

Completion date

May, 2028

Anticipated

Primary completion date

May, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.
  • Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.
  • Age ≥ 18 years at the time of consent.
  • Tumors must have PD-L1 Combined Positive Score (CPS) ≥ 1.
  • ECOG or Karnofsky Performance Status of 0-1
  • Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) within 30 days prior to treatment .

Exclusion Criteria:

  • Known HPV-positive cancer
  • Active infection requiring systemic therapy.
  • Prior treatment with XL-092
  • Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).

Study Design

Enrollment

26 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Locally advanced oral cavity squamous cell carcinoma

Locally advanced oral cavity squamous cell carcinoma (OCSCC) with surgically resectable disease.

Interventions

XL092

60 mg oral once a day

Pembrolizumab

200 mg intravenous for 30 minutes in every 21 days for

Primary outcome measure

  • Rate of pathologic response [ Time Frame: Up to 66 days ]

Central Contacts and Locations

Locations

University of North Carolina at Chapel Hill

Recruiting

Chapel Hill, North Carolina, United States, 27599

Contacts

More Information

Sponsor

UNC Lineberger Comprehensive Cancer Center

Last update posted

Nov 19, 2026

Last verified

Nov, 2026

Keywords

  • surgically resectable
  • neoadjuvant treatment
  • XL092
  • pembrolizumab
  • pathologic response
  • HPV negative

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by UNC Lineberger Comprehensive Cancer Center on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.